Antibodies to growth hormone drugs originate from GH monomers and polymers with altered structures in two main ways: 1. During the freeze-drying process, water molecules are subjected to temperature changes and volume expansion, resulting in structural changes due to the extrusion of protein monomers. 2, during the lyophilization process, the absence of hydrated membrane on the protein surface leads to the polymerization of multiple protein monomers, resulting in polymers. The antibody can be metabolized by itself, but the channel and time cannot be controlled, and will be produced immediately when the patient is re-dosed, and the concentration will increase in leaps and bounds. The risk of antibody production cannot be avoided even if the patient discontinues the drug, and the immune complexes are deposited and accumulate in the slower metabolizing fraction. The long-term risk to patients from antibody production is significant, as antibody and antigen binding can easily produce immune complexes that can be deposited in organs with slow blood flow, such as the kidneys and joints, leading to chronic glomerulonephritis, serum sickness, rheumatoid arthritis, and other diseases, posing long-term safety risks and hazards. The EU Drug Evaluation Center also clearly stipulates that immunogenicity testing is an integral part of the clinical safety evaluation of biological agents, and children are a high-risk group for antibodies, so the safety of drugs should be more concerned in the clinical treatment of children. In contrast, the SAI water enhancer is safer because it does not undergo freeze-drying, the protein structure returns to its natural conformation and does not increase the production of polymers, with zero detection of antibodies.